FDA grants Breakthrough Therapy designation to pexidartinib

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted Breakthrough Therapy Designation to pexidartinib (formerly PLX3397) for the treatment of tenosynovial giant cell tumor where surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity.

Currently, there is no FDA-approved systemic therapy for the treatment of TGCT. The designation was granted based on results from an extension cohort of a single-arm, multi-center phase I study that assessed the safety and efficacy of pexidartinib. Results of this study were published in The New England Journal of Medicine.

A pivotal phase III trial of pexidartinib called ENLIVEN is currently enrolling patients with symptomatic TGCT for whom surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity.

Pexidartinib is an oral small molecule that potently and selectively inhibits colony stimulating factor-1 receptor, which is a primary growth driver of abnormal cells in the synovium that causes TGCT. Pexidartinib has not been approved by FDA or any other regulatory authority for uses under investigation.

In addition to Breakthrough Therapy Designation, pexidartinib has been granted Orphan Drug Designation by FDA for the treatment of PVNS and GCT-TS. Pexidartinib also has received Orphan Designation from the European Commission for the treatment of TGCT. Pexidartinib is sponsored by Daiichi Sankyo Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group.

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login